T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 28, Issue 2, Pages 353-362
Publisher
Springer Science and Business Media LLC
Online
2022-01-14
DOI
10.1038/s41591-021-01623-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mapping the immune environment in clear cell renal carcinoma by single-cell genomics
- (2021) Nicholas Borcherding et al. Communications Biology
- Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis
- (2021) James A. Hutchinson et al. Nature Communications
- CD4+ T cells are essential for the development of destructive thyroiditis induced by anti–PD-1 antibody in thyroglobulin-immunized mice
- (2021) Yoshinori Yasuda et al. Science Translational Medicine
- Integrative bulk and single-cell profiling of pre-manufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy
- (2021) Gregory M Chen et al. Cancer Discovery
- Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
- (2021) Lauren J Brown et al. Journal for ImmunoTherapy of Cancer
- Integrated analysis of multimodal single-cell data
- (2021) Yuhan Hao et al. CELL
- Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
- (2021) Miles C. Andrews et al. NATURE MEDICINE
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
- (2021) Golnaz Morad et al. CELL
- Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
- (2020) N. Chaput et al. ANNALS OF ONCOLOGY
- Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma
- (2020) Benjamin P. Fairfax et al. NATURE MEDICINE
- Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
- (2020) Barzin Y. Nabet et al. CELL
- T-cell repertoire analysis and metrics of diversity and clonality
- (2020) Johanna Chiffelle et al. CURRENT OPINION IN BIOTECHNOLOGY
- Pruritus and Tense Bullae After Discontinuation of Pembrolizumab in a Patient With Renal Cell Carcinoma
- (2020) Amy K. Bieber et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients
- (2020) Si-Qi Tang et al. Cancer Research and Treatment
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Determining cell type abundance and expression from bulk tissues with digital cytometry
- (2019) Aaron M. Newman et al. NATURE BIOTECHNOLOGY
- Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated with Immune‐Checkpoint Inhibitors
- (2019) Alberto Pavan et al. ONCOLOGIST
- Comprehensive Integration of Single-Cell Data
- (2019) Tim Stuart et al. CELL
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
- (2019) Douglas B. Johnson et al. NATURE MEDICINE
- Development of a Comprehensive Antibody Staining Database Using a Standardized Analytics Pipeline
- (2019) El-ad David Amir et al. Frontiers in Immunology
- Concordance between gene expression in peripheral whole blood and colonic tissue in children with inflammatory bowel disease
- (2019) Nathan P. Palmer et al. PLoS One
- Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
- (2019) Salahaldin A. Tahir et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
- (2019) David Liu et al. NATURE MEDICINE
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Early B cell changes predict autoimmunity following combination immune checkpoint blockade
- (2018) Rituparna Das et al. JOURNAL OF CLINICAL INVESTIGATION
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Case of Nivolumab‐Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein‐1/Programmed Death Ligand‐1 Inhibitors and Recommendations for Diagnosis and Management
- (2018) Adriana T. Lopez et al. ONCOLOGIST
- Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
- (2018) Taku Fujimura et al. Oncotarget
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
- (2018) Noam Auslander et al. NATURE MEDICINE
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function
- (2018) Eric Shifrut et al. CELL
- Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
- (2018) Su Y. Lim et al. CLINICAL CANCER RESEARCH
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- A functional genomics predictive network model identifies regulators of inflammatory bowel disease
- (2017) Lauren A Peters et al. NATURE GENETICS
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of responses to immune checkpoint blockade in advanced melanoma
- (2017) N. Jacquelot et al. Nature Communications
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire
- (2016) Jennifer S. Sims et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
- (2016) Sumit K. Subudhi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data
- (2015) Sofie Van Gassen et al. CYTOMETRY PART A
- Diagnosis and risk stratification in patients with anti-RNP autoimmunity
- (2015) M F Carpintero et al. LUPUS
- The prognostic landscape of genes and infiltrating immune cells across human cancers
- (2015) Andrew J Gentles et al. NATURE MEDICINE
- MiXCR: software for comprehensive adaptive immunity profiling
- (2015) Dmitriy A Bolotin et al. NATURE METHODS
- Robust enumeration of cell subsets from tissue expression profiles
- (2015) Aaron M Newman et al. NATURE METHODS
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression
- (2015) T. Hung et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads
- (2014) Hongshan Jiang et al. BMC BIOINFORMATICS
- CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
- (2014) L. Robert et al. CLINICAL CANCER RESEARCH
- Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
- (2013) Vafa Shahabi et al. Journal of Translational Medicine
- viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia
- (2013) El-ad David Amir et al. NATURE BIOTECHNOLOGY
- The significance of OX40 and OX40L to T-cell biology and immune disease
- (2009) Michael Croft et al. IMMUNOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started